Friedreich's Ataxia Market Report Metrics . Details . Study Period. 2020–2034. Coverage. 7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].

Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites ...

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 Provided by GlobeNewswire Jun 4, 2025, 11:00:00 AM ...

Huntington’s disease and Friedreich’s ataxia are part of a group of neurological disorders dubbed trinucleotide repeat disorders because they are caused by repeating three-letter stretches of DNA.

IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites CARLSBAD, Calif., June 04, 2025 (GLOBE NEWSWIRE ...

Design Therapeutics announces initial safety data for DT-216P2 in Friedreich ataxia trial; FDA places clinical hold on U.S. site expansion. Quiver AI Summary ...

Friedreich's Ataxia, a Debilitating Disease. About one of every 20,000 to 50,000 people in the United States has Friedreich's ataxia, which is caused by a genetic defect that prevents adequate ...

Cardiac prophylactic treatment began before age 14 for 27.7% of the cohort. Compared with patients not treated prophylactically, treatment was associated with a 54% reduction in death.

Jemima Hawkesby and university friends of Flynn Mitchell are fundraising for a cure for Friedreich’s ataxia (FA). The life-shortening, progressive neuro-muscular disorder has no cure.

Most Hamilton and Waikato MRI radiology services will merge under a joint venture proposal from the region’s radiology companies being considered by competition watchdog the Commerce Commission.